top of page
Profile
Join date: Mar 23, 2023
Posts (34)
Dec 2, 2025 ∙ 3 min
Laxxon Medical’s Levodopa / Carbidopa (LXM.5) Oral Dosage Form Demonstrates Significantly Higher Bioavailability (>380%) Compared to Sinemet®, Study Results Published in the Journal Pharmaceutics
SPID ® -Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. NEW YORK--( BUSINESS WIRE )--Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the publication of a new study in the Journal Pharmaceutics (MDPI) that highlights the effectiveness of its proprietary...
57
0
Aug 11, 2025 ∙ 3 min
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
NEW YORK--( BUSINESS WIRE )--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced...
185
0
Mar 11, 2025 ∙ 4 min
Laxxon's Oral GLP-1 Agonist Treatment, LXM.2, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.
84
0
Laxxon Medical
Writer
More actions
bottom of page